Sutent for pancreatic cancer – pro
Sutent® (sunitinib malate) has been shown to significantly increase progression-free survival in patients with advanced pancreatic islet cell tumors, leading to a halt in the Phase III trial. For pancreatic adenocarcinoma, preliminary analysis of a large cooperative group phase II study suggests modest single agent activity. There is an ongloing phase II trial: Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine, NCT00397787.
Pfizer Inc. Press Release March 12, 2009: http://mediaroom.pfizer.com/news/pfizer/20090312005308/en
Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology. 26:3403-3410
O’Reilly, E. M., Niedzwiecki, D., Hollis, D. R., Bekaii-Saab, T. S., Pluard, T., Duffy, A., Overcash, F., Ivy, S. P., Goldberg, R. M.
A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603
J Clin Oncol (Meeting Abstracts) 2008 26: 4515
Burris, Howard, III , Rocha-Lima, Caio
New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways
Oncologist 2008 13: 289-298; doi:10.1634/theoncologist.2007-0134